1/2 the price, has products in development other than Illuvien. Granted if not approved, PSDV will take a hit.
ALIM, appears to be exclusively set up for selling 1 product upon approval. What happens if it doesn't get approved?
Now, of course, that all gets flipped if the FDA approves the drug, then if successfully manufactured and marketed, ALIM, get the lion's share of the benefit, while PSDV will get residuals/royalty payments.